Just Because You Can Personalize to One, Should You? Pharma Marketing’s Next Question

On a Fierce Pharma panel in Philadelphia in September 2026, commercial leaders were asked about the next era of marketing growth. One panelist described a personalization strategy that runs the full cycle: segment, build a profile, develop insights, create content variations, orchestrate the journey to individuals, then learn from the result and feed it back.

What’s new is the middle of that loop. Producing the right content variation, and getting it approved quickly, used to be the hard part. AI has largely removed that bottleneck.

The moderator then asked the question that matters more: just because you can reach n=1, should you?

Measure patient impact, not targeting precision

It’s easy to justify a personalization budget by pointing at how finely you can target. The panel’s answer was to measure it against whether the journey creates real impact for the healthcare professional, the patient or the payer. Precision is a means. If a more tailored message doesn’t change what a clinician does or what a patient experiences, it’s cost, not value. (It’s the same trap I see in SEO, where teams report deliverables instead of outcomes.)

This is consistent with older evidence. An IQVIA white paper from 2018 found that what healthcare professionals say they prefer often diverges from what they receive, with most groups in every market still naming face-to-face contact first. It argued for building a “segment of one” view of each high-value physician and refining it continuously with observed responses, not just stated preferences. The practical lesson: personalization is a learning loop, and the “learn” step is where the return is.

Personalization is heading toward table stakes

A second panelist argued that personalization won’t stay a differentiator. Everyone is moving in the same direction, whatever their reasons. The panel compared where AI stands today to where the internet stood in its early years.

If everyone can personalize, what separates companies is what surrounds it: the human layer. As one panelist put it, there’s a real difference between knowing something about a customer and truly understanding their experience.

The rep gets more valuable, not less

The panel pushed back on the idea that AI makes the field rep less important. The argument was the opposite: a rep with data at their fingertips can have a more engaging, more empathetic conversation about complex problems. Another speaker added a reminder that many physician offices still rely on fax and phone, so the right answer is often a blend of digital and analog, with the data personalizing both.

Takeaways for commercial teams

1. Define the impact metric first. Decide what a better outcome looks like for the HCP or patient before you scale variants.
2. Treat personalization as a learning system. Build the feedback step into the plan, not as an afterthought. (The same idea drives self-improving AI workflows.)
3. Invest in the human layer. Use AI to prepare reps and medical teams for better conversations, not to replace them.
4. Keep analog channels in the mix where your audience still uses them.
5. Plan for parity. Assume competitors will match your personalization; decide now what you’ll do that’s harder to copy.

This is the first of five posts from the panel. Next: AI suggestions that field teams actually act on.

Working on AI-driven marketing in a regulated industry? Get in touch.